

Burton Angrist

Bibliography

Original Reports

1. Angrist B, Schweitzer J, Friedhoff AJ and Gershon S: Survey of the effects of banana smoking and chromatographic analysis of the baked skins. *NY State J. Med* 1967; 29:504-513.
2. Angrist B, Schweitzer J, Friedhoff AJ, Gershon S, Hekimian LJ and Floyd A: The clinical symptomatology of amphetamine psychoses and its relationship to amphetamine levels in urine. *Int Pharmacopsychiatry* 1969; 2:125-139.
3. Angrist B and Gershon S: Amphetamine abuse in New York City, 1966-1968. *Seminars in Psychiatry* 1969; 1:195-207.
4. Angrist B: Reported effect of STP - The unreliability of hippies as reporters of drug effects. *Brit J. Addict* 1969; 64:321-134.
5. Angrist B, Schweitzer JW, Friedhoff AJ, Gershon S: Investigation of p-methoxy-amphetamine excretion in amphetamine induced psychosis. *Nature* 1970; 225:652-652.
6. Angrist B, Schweitzer JW, Gershon S and Friedhoff AJ: Mephentermine psychosis - misuse of the Wyamine inhaler. *Am J Psychiatry* 1970; 126:1315-1317.
7. Angrist B, Gershon S, Levitan SJ and Blumberg AG: Lithium induced diabetes insipidus-like syndrome. *Comp Psychiatry* 1970; 11:141-145.
8. Angrist B and Gershon S: The of experimentally induced amphetamine psychosis preliminary observations. *Biol Psychiatry* 1970; 2:95-107.
9. Willner J, Samach M, Angrist B, Wallach MB, and Gershon S: Drug induced stereotyped behavior and its antagonism in dogs. *Comm Behav Biol* 1970; part A 5:135-141.
10. Schweitzer J, Friedhoff AJ, Angrist B, and Gershon S: Excretion of p-methoxyamphetamine administered to humans. *Nature* 1971; 229:133-134.
11. Angrist B, Shopsin B and Gershon S: The comparative psychotomimetic effects of stereoisomers of amphetamine. *Nature* 1971; 234:152-153.
12. Wallach MB, Angrist B and Gershon S: The comparison of the stereotyped behavior induced effects of d- and l-amphetamine in dogs. *Comm Behavior Biol* 1971; 6: 93-96.
13. Alpert M, Angrist B, Diamond F and Friedhoff, AJ: Effects of high doses of amphetamine on digital tremor in volunteers pre treated with agents which alter biogenic amines. *Nat Acad Sci - Nat Rs council*, 1971; 11:1670-1609.
14. Angrist B, Shopsin B, Gershon S and Wilk S: Monamine metabolites in urine and cerebrospinal fluid after large dose amphetamine administration. *Psychopharmacologica* 1972; 26:1-9.
15. Rotrosen J, Wallach M, Angrist B and Gershon S: Antagonism of apomorphine-induced stereotypy and emesis in dogs by thioridazine, haloperidol and pimozide. *Psychopharmacologia* 1972; 26:185-194.
16. Rotrosen J, Angrist B, Wallach NM and Gershon S: Absence of serotonergic influence on apomorphine-induced stereotypy. *Europ J Pharmacol* 1972; 2 0:133-135.

17. Angrist B and Gershon S: Behavioral profile of a potent new psychotoxic compound. *Psychopharmacologia* 1973; 30:109-114.
18. Angrist B, Sathananthan G and Gershon S: Behavioral effect of 1-DOPA in schizophrenic patients. *Psychopharmacologia* 1973; 31:1-12.
19. Sathananthan G, Angrist B and Gershon S: Response threshold to 1-DOPA in psychiatric patients. *Biol Psychiatry* 1973; 7:139-146.
20. Angrist B, Sathananthan G, Wilk S and Gershon S: Amphetamine psychosis: Behavioral and Biochemical aspects. *J. Psychiat Res* 1974; 11:13-23.
21. Angrist B, Wilk S and Gershon S: The effect of probenecid and large dose amphetamine administration on cerebrospinal fluid homovanillic acid. *Biol Psychiatry* 1974; 8:113-114.
22. Angrist B, Lee HK and Gershon S: The antagonism, of amphetamine induced symptomatology by a neuroleptic. *Amer J Psychiatry* 1974; 131:817-819.
23. Angrist B, Urcuyo L and Gershon S: Response to incremental doses of Ditrin in abstinent alcoholics and drug users. *Comprehensive Psychiatry* 1974; 15:2201-204.
24. Angrist B, Rotrosen J and Gershon S: Assessment of tolerance to the hallucinogenic effects of DOM. *Psychopharmacologia* 1974; 36:203-207.
25. Angrist B, Thompson H, Shopsin B and Gershon S: Clinical studies with dopamine receptor stimulants. *Psychopharmacologia* 1975; 44- 273-280.
26. Angrist B, Gershon S, Sathananthan G, Walker RW, Lopez-Ramos B, Madel LR and Vandenneuvel WJA: Dimethyltryptamine levels in blood of schizophrenic patients and control subjects. *Psychopharmacologia* 1976; 47:29-32.
27. Rotrosen J, Angrist B, Gershon S, Sachar EJ and Halpern F: Dopamine receptor alteration in schizophrenia: neuroendocrine evidence. *Psychopharmacology* 1976; 51:1-7.
28. Angrist B, Rotrosen J, Kleinberg, D, Merriam V and Gershon S: Dopaminergic agonist properties of ephedrine. *Psychopharmacology* 1977; 55:115-120.
29. Rotrosen J, Angrist B, Gershon S, Aronson M, Guruen P, Sachar EJ, Enning RK, Matthyse S, Stanley M and Wilk S: Thiethylperamine: Clinical antipsychotic efficacy and correlation with potency in predictive systems. *Arch Gen Psychiatry* 1978; 35:949-951.
30. Rotrosen J, Angrist B, Clark C, Gershon S, Sachar EJ and Halpern F: Suppression of Prolactin by dopamine agonists in schizophrenics and controls. *Amer J Psychiatry* 1978; 135:949-951.
31. Serby M, Angrist B and Lieberman A: Mental disturbances during bromocryptine and lergotrile treatment of Parkinson's disease. *Amer J Psychiatry* 1978; 135:227-229.
32. Angrist B, Ain M, Rotrosen J, Gershon S, Sachar EJ and Halpern F: Behavioral and Neuroendocrine effects of low dose ET-495 Antagonism by haloperidol. *J. Neural Trans* 1979; 44:249-262.
33. Angrist B and Gershon S: Variable attenuation of amphetamine effects by lithium. *Amer J Psychiatry* 1979; 136:806-810.

34. Rotrosen J, Angrist B, Gershon S, Pacquin J, Brachney L, Oleshansky M, Halpern F and Sachar EJ: Neuroendocrine effects of apomorphine: Characterization of response patterns and application to schizophrenia research. *Brit J Psychiatry* 1979; 135:444-446.
35. Angrist B, Rotrosen J and Gershon S: Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. *Psychopharmacology* 1980; 67:31-38.
36. Lautin A, Stanley M, Angrist B, Gershon S, Heckl K and Karobath M: The effect of sodium valproate on schizophrenic psychopathology. *Brit J Psychiatry* 1980; 137:240-244.
37. Angrist B, Rotrosen and Gershon S: Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. *Psychopharmacology* 1980; 72:17-19.
38. Woogen S, Graham J and Angrist B.- A tardive dyskinesia-like syndrome after amitriptyline treatment. *J Clinical Psychopharmacology* 1981; 1:34-36.
39. Angrist B, Peselow E, Rubenstein M, Corwin J and Rotrosen J: Partial improvement in negative schizophrenic symptoms after amphetamine. *Psychopharmacology* 1982; 78:128-130.
40. Smith M, Angrist B and Cooper T- Seizures associated with a high plasma maprotiline level. (Letter) *J Clinical Psychopharmacol* 1983; 3:57-58.
41. Serby K Angrist B, Corwin J, Funari D, Sudelovsky A, Siekierski J, Peselow E and Rotrosen J: Cholestokinen octapeptide in dementia. *Psychopharmacology Bull* 1984; 20: 546-547.
42. Angrist B, Peselow E, Rubenstein M, Wolkin A and Rotrosen J: Amphetamine response and relapse risk after depot neuroleptic discontinuation. *Psychopharmacology* 1985; 85:277-283.
43. Kupietz SS, Bartlik B, Angrist B and Winsberg B: Psychostimulant plasma concentration and learning performance. *J Clin Psychopharmacol* 1985; 5:193-295.
44. Adler L, Angrist B, Peselow E, Corwin J and Rotrosen J: Efficacy of Propranolol for neuroleptic-induced akathisia. *J Clin Psychopharmacol* 1985; 5:164-166.
45. Volkow N, Brodie J, Wolf A, Russell JAG, Angrist B and Cancro R: Brain metabolism in schizophrenia before and after acute neuroleptic administration. *Neurology, Neurosurgery and Psychiatry* 1986; 49:1199-1202.
46. Adler L, Angrist B, Peselow E, Corwin J, Maslansky R and Rotrosen J: A controlled assessment of propranolol in the treatment of neuroleptic induced akathisia. *Br J Psychiatry* 1986; 149:42-45.
47. Wolkin A, Angrist B, Wolf A, Brodie J, Fowler J, Jordan B, Jaeger J, Cancro R and Rotrosen: Effects of Amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by P.E.T. Using (I 1-c) - 2 deoxyglucose. *Psychopharmacology* 1987; 92:241-246.
48. Peselow E, Angrist B, Sudilovsky A, Corwin J, Siekierski J, Trent F, and Rotrosen J: Double blind trials of cholecystokinin octapeptide in neuroleptic refractory schizophrenia. *Psychopharmacology* 1987; 92:241-246.
49. Adler L, Angrist B, Peselow E, Reitano J and Rotrosen J: Efficacy of clonidine in neuroleptic induced akathisia. *Am J Psychiatry* 1987; 144: 235-236.

50. Angrist B, Corwin J, Bartlik B, Rotrosen J and Cooper T: Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. *Biol Psychiatry* 1987; 22: 1357-1368.
51. Reiter S, Adler L, Angrist B, Corwin J and Rotrosen J- Effects of atenolol and propranolol in neuroleptic-induced akathisia. *J Clin Psychopharmacol* 1987; 7:279-280.
52. Angrist B, Smith M, Alder L, Peselow E and Rotrosen J: Preliminary Studies of Clonidine in Psychotic Patients. *J Neural Trans* 1988; 71:115-121.
53. Wolkin A, Angrist B, Wolf A, Brodie J, Wolkin B, Jaeger J, Cancro R and Rotrosen J: Decreased frontal glucose utilization in chronic schizophrenics: A replication study. *Am J Psychiatry* 1988; 145:251-253.
54. Smith M, Wolf AP, Brodie JD, Arnett CD, Barouche F, Shuie CY, Fowler JS, Russel JAG, MacGregor RR, Wolkin A, Angrist B, Rotrosen J and Peselow E: Serial [18F]-N-Methylspiroperidol PET Studies to Measure Changes in Antipsychotic Drug D2 Receptor Occupancy in Schizophrenic patients. *Biol Psychiatry* 1988; 23:653-663.
55. Reiter S, Adler L, Angrist B, Peselow E and Rotrosen J: Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. *J Clin Psychiatry* 1989; 50: 26-27.
56. Meiselas KD, Spencer EK, Oberfield RA, Peselow EP, Angrist B, Campbell M: Differentiation of stereotypes from neuroleptic-related dyskinesia in autistic children. *J Clin Psychopharmacol* 1989; 9:207-209.
57. Douyan R, Angrist B, Peselow E, Cooper T and Rotrosen J: Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. *Am J Psychiatry* 1989; 146:231-234.
58. Adler L, Duncan E, Angrist B and Rotrosen J: Effects of a B2 selective antagonist in neuroleptic-induced akathisia. *Psychiatry Research* 1989; 27:1-4.
59. Kim A, Adler L, Angrist B and Rotrosen J: Efficacy of low dose metoprolol in neuroleptic-induced akathisia. *J Clin Psychopharmacol* 1989; 9:294-296.
60. Borod J, Peselow E, Angrist B and Leiberman A: A preliminary comparison of flat affect schizophrenics and brain damaged patients on measures of affective flattening. *J of Communication Disorders* 1989; 22:-93-104.
61. Peselow E, Angrist B and Rotrosen J: Changes in tardive dyskinesia after fluphenazine decanoate discontinuation. *Annals of Clin Psychiatry* 1989; 1: 189-191.
62. Brody D, Adler L, Kin A, Angrist B and Rotrosen J: Effects of buspirone in seven schizophrenic subjects *J Clin Psychopharmacol*. 1990; 10:68-69.
63. Wolfsohn R and Angrist B: A pilot trial of levodopa/carbidopa in early cocaine abstinence. *J Clin Psychopharmacol*. 1990; 10:440-442.
64. Duncan E, Adler L, Angrist B and Rotrosen J: Nifedipine in the treatment of tardive dyskinesia. *J Clin Psychopharmacol*. 1990; 10:414-416.
65. Nemes Z, Rotrosen J, Angrist B, Peselow E and Schoentag R: Serum iron levels and akathisia. *Biol Psychiatry* 1991; 29:411-413.
66. Adler L, Angrist B, Fritz P, Rotrosen J, Mallya G, and Lipinski J: Lack of efficacy of d-propranolol in neuroleptic-induced akathisia. *Neuropsychopharmacology* 1991; 4:109-116.

67. Adler L, Angrist B, Rotrosen J: Efficacy of betaxalol in neuroleptic-induced akathisia. *Psychiatry Research* 1991; 39: 193-198.
68. Dewey SL, Logan J, Wolf AP, Brodie JD, Angrist B, Fowler JS and Volkow ND: Amphetamine induced decreases in (F-18) N-methylspiroperidol binding in the baboon brain using Position Emission Tomography (PET) *Synapse* 1991; 7:324-327.
69. Logan J, Dewey S, Wolf AP, Fowler JS, Brodie JD, Angrist B, Avolhow N and Gatley SJ: Effects of endogenous dopamine on measures of 18F N-methylspiroperidol. Binding in basal ganglia: Comparison of simulations and experimental results from PET studies in baboons. *Synapse* 1991; 9:195-201.
70. Bartlett E, Barouche F, Brodie JD, Wolkin A, Angrist B, Rotrosen J and Wolf A: Stability of resting deoxyglucose metabolic values in PET studies in schizophrenia. *Psychiatry Research: Neuroimaging* 1991; 40:11-20.
71. Angrist B, d'Hollosy M, Sanfilippo K, Satreano J, Diamond G, Simberkoff M and Weinreb H: CNS stimulants as symptomatic treatments for AIDS - related neuropsychiatric impairment. *J. Clin Psychopharmacol.* 1992; 12:268-272.
72. Wolkin A, Sanfillipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J: Negative symptoms and hypofrontality in chronic schizophrenia. *Arch Gen Psychiatry* 1992; 49:959-965.
73. Wolfsohn R, Sanfilippo K and Angrist B: A placebo controlled trial of L DOPA/Carbidopa in early cocaine abstinence. *Neuropsychopharmacology* 1993; 9:49-53.
74. Napoen NL, Sanfilippo M, Samanach K, Ryer H, Ko G, Angrist B, Wolkin A, Rotrosen J: Elevated PLA-2 activity in schizophrenics and other psychiatric patients. *Biol Psychiatry* 1993; 34:641-649.
75. Duncan E, Wolkin A, Angrist B, Sanfilippo M, Wieland S, Cooper TB, Rotrosen J: Plasma homovanillic acid in neuroleptic responsive and non-responsive schizophrenics. *Biol Psychiatry* 1993; 34:523-528.
76. Volkow ND, Fowler JS, Wang GS, Dewey SL, Schlyer D, MacGregor R, Yogan J, Alexoff D, Shea C, Hitzemann R, Angrist B and Wolf AP: Reproducibility of repeated measures of carbon-11 raclopride binding in human brain. *J Nucl. Med* 1993; 34:609-613.
77. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, and Angrist B: Vitamin E treatment of tardive dyskinesia. *Am J Psychiatry* 1993; 150:1405-1407.
78. Wolkin A, Sanfillipo M, Angrist B, Duncan E, Wieland S, Wolf AP, Brodie JD, Cooper T and Rotrosen J: Acute Amphetamine Challenge in Schizophrenics: Effects on cerebral glucose utilization and clinical symptomatology. *Biol Psychiatry* 1994; 36:317-325.
79. Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, Mac Gregor R, Burr G, Cooper T, Wolf AP: Imaging endogenous dopamine competition with [11C] raclopride in the human brain. *Synapse* 1994; 16:255-262.
80. Adler L and Angrist B: Paroxetine and akathisia. *Biol Psychiatry.* 1995; 37:336-337.
81. Wyatt RJ, Angrist B, Karum F: Urinary dopamine metabolites during cocaine abstinence. Submitted 6/10/94 *Am J. Addiction.. The Am. J. on Addictions* 1995; 4:133-140.
82. Sanfilippo M, Wolkin A, Angrist B, van Kammen DP, Duncan E, Wieland S, Cooper TB, Peselow ED and Rotrosen J: Amphetamine and Negative Symptoms of Schizophrenia. *Psychopharmacology* 1996; 123:211-214.

83. Volkow ND, Wang GJ, Gotley SJ, Fowler JS, Ding TS, Logan J, Hitzemann R, Angrist B, and Lieberman J: Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and the behavioral and cardiovascular effects. *Psychopharmacology* 1996; 123:26-33.
84. Wolkin A, Sanfilipo M, Duncan E, Angrist B, Wolf AP, Cooper TB, Brodie JD, Laska E, Rotrosen J: Blunted changes in cerebral glucose utilization after haloperidol treatment in schizophrenia patients with prominent negative symptoms. *Am J. Psychiatry* 1996; 153:346-354.
85. Eberstein S, Adler L, and Angrist B: Nefazodone and Akathisia. *Biol Psychiatry*, 1996; 40:798-799.
86. Bartlett E, Hallin A, Chapman B, Angrist B: Selective Sensitization to the psychosis -inducing effects of cocaine: a possible marker for addiction relapse vulnerability: *Neuropsychopharmacology* 1997; 16:77-82.
87. Volkow ND, Wang GJ, Fowler JS, Yoyan J, Angrist B, Hitzemann R, Lieberman J and Papas N: Effects of methylphenidate on regional brain glucose metabolism in human; relationship to dopamine D2 receptors *Am. J. Psychiatry* 1997; 154:50-55.
88. Wang GJ, Volkow ND, Wong C, Hitzemann RJ, Angrist B, Burr G, Paseani K, Pappas N, Lu A, Cooper R, Lieberman J: Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. *European Addiction Research* 1997; 3:49-54.
89. Volkow ND, Wang GJ, Fowler JS, Hitzemann RJ, Angrist B, Gatley SJ, Logan J, Ding TS, Papas N: Methylphenidate induced craving in cocaine abusers is associated with changes in right striato-orbitofrontal metabolism: implications in addiction, *Am. J. Psychiatry* 1999; 156:19-26.
90. Efferen TR, Duncan EJ, Szilagyi S, Chakovorty S, Adams J, Gonzenbach S, Angrist B, Butler PD, Rotrosen J. Diminished acoustic startle in chronic cocaine users. *Neuropsychopharmacology* 2000; 22:89-96.
91. Duncan E, Adler L, Stephanides M, Sanfilipo M and Angrist B. Akathisia and exacerbation of psychopathology. A preliminary report. *Clinical Neuropsychopharmacology* 2000; 23:169-173.
92. Duncan, EJ, Madonich S., Parwani A, Angrist B, Rojan R, , Chakovorty S, Efferen T, Szilagyi S, Stephanides M, Chappell P. Clinical and sensorimotor gating effects of ketamine in normals. *Neuropsychopharmacology*. In Press.
93. Duncan, E, Madonich S, Chakovorty S, Parwani A, Szilagyi S, Efferen T, Gozenbacg F. Effects of smoking on acoustic startle and prepulse inhibition in humans. *Psychopharmacology* 2001; 156:266-272.
94. Angrist B, Sanfilipo M and Wolkin A. Cardiovascular effects of oral d-amphetamine (0.5 mg/kg) and attenuation by haloperidol. *Clinical Neuropharmacology* 2001; 24:139-144.

95. Reid, M, Cipler D, O'Leary S, Angrist B. Sensitization to the psychosis inducing effects of cocaine compared with measures of cocaine craving and cue reactivity. *The American Journal on Addictions*. 13:305-315, 2004.
96. Reid, M, Angrist B, Baker S, Woo C, Schwartz M, Montgomery A, Majewska D, Robinson, J, and Rotrosen J. A placebo-controlled screening trial of celecoxib for the treatment of cocaine-dependence. *Addiction*: 100 (Suppl. 1) 32-34, 2005.
97. Reid, M, Angrist B, Baker S, O'Leary S, Stone J, Schwartz M, Lederman O, Montgomery A, Elkashef A, Majewska D, Robinson S and Rotrosen J. A placebo-controlled, double-blind study of mecamylamine treatment for cocaine dependence in patients enrolled in an opiate replacement program. *Substance Abuse* 26 (2): 5-14, 2006.

Non Peer Reviewed Original Reports

1. Angrist B, Gershon S and Floyd A: Psycho-activating effects of a new anticonvulsant-CM-6. *Curr Ther Res* 1968: 10: 237-243.

2. Sathananthan G, Angrist B, Phillip N and Gershon S: Assessments of Antipsychotic Activity of a Butyrophenone Analogue Lemperone (AHR 2277). *Curr Ther Res* 1974; 16:844-847.
3. Sathananthan G, Rick W, Matz R and Angrist B: Psychomotor effects of a new CNS Stimulant - Abbot 34519. *Curr Ther Res* 1974; 16:1177-1180.
4. Angrist B, Rotrosen J, Aronson M and Gershon S: A clinical trial of a morphanthridine derivative in schizophrenic patients - lack of extrapyramidal symptoms. *Curr Ther Res* 1976; 20:94-98.
5. Rotrosen J, Angrist B, Pacquin J, Gurland M, Brachney L and Gershon S: Neuroendocrine studies with dopamine agonists in schizophrenia. *Psychopharmacology Bull* 1978; 14:14-17.
6. Lautin A, Stanley M, Angrist B and Gershon S: Extrapyramidal syndrome with sodium valproate. *IRCS Medical Science* 1979; 7:569.
7. Angrist B, Rotrosen J and Gershon S: Assessment of dopaminergic function in schizophrenia. *Psychopharmacology Bull* 1980; 16:59-60.
8. Serby K Angrist B, Corwin J, Funari D, Sudelovsky A, Siekierski J, Peselow E and Rotrosen J: Cholestokinen octapeptide in dementia. *Psychopharmacology Bull* 1984; 20: 546-547.
9. Adler L, Angrist B, Peselow E, Corwin J, and Rotrosen J: Noradrenergic mechanisms in neuroleptic-induced akathisia: Treatment with propranolol and clonidine. *Psychopharmacology Bull* 1987; 23: 21-25.
10. Adler L, Reiter S, Corwin J, Hemdal P, Angrist B and Rotrosen J: Differential effect of propranolol and benztropine in patients with neuroleptic-induced akathisia. *Psychopharmacology Bull* 1987; 23: 519-521.
11. Adler L, Duncan E, Reiter S, Angrist B, Peselow E and Rotrosen J: Effects of calcium channel antagonists on tardive dyskinesia and psychosis. *Psychopharmacology bull* 1989; 24:421-425.
12. Adler L, Duncan E, Kim A, Hemdal P, Rotrosen J and Angrist B: Akathisia: Selective beta blockers and rating instruments. *Psychopharmacology Bull.* 1989; 25:451-456.
13. Adler LA, Angrist B, Weinreb W, and Rotrosen J: Studies in the time course and efficacy of B blockers in neuroleptic - induced akathisia and the akathisia of idiopathic Parkinson's disease. *Psychopharmacol. Bull.* 1991; 127:107-11.
14. Adler LA, Peselow E, Rosenthal M, Angrist B: A controlled comparison of the effects of propranolol benztropine and placebo on akathisia. An interim analysis. *Psychopharmacology Bulletin* , 1993; 29:283-286.

Proceedings of Meetings

1. Alpert M, Angrist B, Diamond F and Gershon S: Comparison of Ditrin intoxication and acute alcohol psychosis. In: *Origin and Mechanisms of Hallucinations*. Plenum Press, New York, 1970; 245-259.
2. Angrist B and Gershon S: A pilot study of mechanisms in amphetamine psychosis utilizing differential effects of d- and l- amphetamine. *Pharmakopsychiatrie Neuro-Psychopharmakologie* 1971; 4-64-75.

3. Gershon S and Angrist B: Amphetamine induced psychosis: A possible approach to assessing pathogenic mechanisms in amphetamine psychosis. Presented at the World Congress of Psychiatry, Mexico, D.F. 1971 (Excerpta medica Int. Congress Series, No. 274), pp 188-125.
4. Angrist B and Gershon S: Possible dose response relationships in amphetamine psychosis. In-. Drug Abuse Proceedings of the International Conference. (Zarafonotis, C, ed.). Lee and Febriger, 1972: 263-269.
5. Angrist B, Sathananthan G, Wilk S, and Gershon S: Behavioral and biochemical effects of I-DOPA in psychiatric patients. In: Frontiers in Catecholamine research (Usdin E and Synder, S, eds.), New York, Pergamon Press, 1973: 991-994.
6. Gershon S and Angrist B: Alterations of cholinergic function on behavior. In: Psychopathology and Pharmacology. (Cole, JO Freedman AM and Friedhoff, AJ eds.) Baltimore, John Hopkins University Press, 1973:15-36.
7. Angrist B and Gershon S. Recent studies on amphetamine psychosis: unresolved issues. In: Current Concepts of Amphetamine Abuse: Symposia Proceedings. (Ellinwood, E H Jr. and Cohen, S, eds.). NIMH U.S. Gov't. Printing Office, 1973.
8. Angrist B and Gershon S: Dopamine and psychotic states: preliminary remarks. In Neuropsychopharmacology of Monoamines and their Regulatory Enzymes. (E. Usdin, ed.) New York: Raven Press, 1974:211-219.
9. Gershon S, Angrist B and Shopsin B: Drugs, Diagnosis and Disease. In: Biology of the Major Psychoses. (Freedman, D X, Ed.) Res Publ Assoc Res Nerv Merit Dis 54. New York: Raven Press, 1975: 85-100.
10. Angrist B, Sathananthan G, Shopsin B and Gershon S: The comparative psychotogenic effects of 1-Dopa and ET-495. In: Cocaine and Other Stimulants. (Ellinwood, E H Jr. and Kilbey, M, eds.). New York: Plenum Publishing Co., 1976.
11. Gershon S, Angrist B and Shopsin B: Pharmacological agents as tools in psychiatric research. In: The Impact of Biology in Modern Psychiatry (Gershon E,H, Belmaker, R H, Kety S and Rosenbaum M, eds). New York: Plenum Publishing Co., 1976: 65-93.
12. Rotrosen J, Angrist B, Gershon S, Sachar EJ and Halpern FS - Neuroendocrine assessments of dopaminergic activity in schizophrenia. In: Advances in Biochemical Psychopharmacology, Vol. 16, (E. Costa and G L Gessa, eds.), New York: Raven Press 1977: 649-653.
13. Angrist B and Gershon S: Clinical response to several dopamine agonist in schizophrenic and non schizophrenic subjects. In: Advances in biochemical Psychopharmacology, Vol. 16, (Costa E and Gessa GL, eds.). Raven Press, 1977: 677-680.
14. Angrist B and Gershon S: Four dopamine agonists: A clinical continuum. In: Neuro Psychopharmacology (Deniker P, Radouco-Thomas C and Villeneuve A, eds.) Oxford and NY: Pergamon Press 1978: 731-738.
15. Angrist B, Peselow E, Rotrosen J and Gershon S: Relationships between responses to dopamine agonists, psychopathology, neuroleptic treatment response, and need for neuroleptic maintenance in schizophrenic subjects. Recent Advances in Neuropsychopharmacology (advances in the BioSciences Vol. 31). Angrist B. et al. eds. Oxford and New York: Pergamon Press 1981.

16. Angrist B and Rotrosen J: Dopaminergic and non-dopaminergic elements in schizophrenia. In: Clinical Pharmacology of Apomorphine and Other Dopaminomimetics. Vol. 2 Clinical Pharmacology. Corsini G U and Gessa, G T, eds. New York: Raven Press, 1981.
17. Angrist B and Tamminga C: "Psychopharmacology and Schizophrenia" (Session Summary) In: Proceedings of 5th International Catecholamine Symposium Gotenberg, Sweden. Part C. Usdin E, Carlsson A, Dahlstrom A, and Engle J (eds.). New York: Allen R Liss Inc. 1984:22-27.
18. Adler L, Lipinski J, Angrist B, Cohen B, Peselow E and Rotrosen J: Beta blockers as a treatment for neuroleptic induced akathisia. *Clinical Neuropharmacology*, 9 (Suppl. 4): 428-430, 1986 (Proceedings 15 CINP Congress, Raven Press, N.Y.).
19. Adler L, Angrist B, Reiter S, Peselow E and Rotrosen J: Adrenergic agents in the treatment of neuroleptic-induced akathisia. In: Schulz SC and Trmminga CA (eds). *Schizophrenia: Scientific Progress* pp. 404-410. Oxford University Press, New York, Oxford, 1989.
20. Angrist B, Sanfilippo M and Wolkin A: Amphetamine response and duration of illness in schizophrenia. *Schizophrenia Research* , 1991:5:200-201.
21. Proceedings of the consensus meeting on the use, abuse and sequellae of abuse of methamphetamine with implications for prevention, treatment and research. DHHS Publication No. (SMA-96-8103), 1997. "Toxic Psychoses" section (pp 19-22) based on paper given June 1996 at the Satellite meeting of C.P.D.D.
22. Yui, K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman, JA, Bracha SH and Ali SF: Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. *Molecular Psychiatry*, 1999:4:512-523.
23. Angrist, B. Prospective clinical studies of the psychiatric effects of amphetamine. *Psychiatry and Clinical Neurosciences*. In Press.

Reviews and Educationally Relevant Publications

1. Gershon S and Angrist B: Drug-induced psychoses. *Hospital Practice* 1967; 2:50-53.
2. Angrist B and Gershon S: Clinical effects of amphetamine and I Dopa on sexuality and aggression. *Comprehensive Psychiatry* 1976; 17:715-722.
3. Angrist B: Toxic manifestations of amphetamine. *Psychiatric Annals* 1978; 8:443-446
4. Angrist B and Van Kammen DP: CNS Stimulants as tools in the study of schizophrenia. *Trends in Neuroscience* 1984; 7:388-390.
5. Adler L, Angrist B, Reiter S and Rotrosen J: Neuroleptic-induced akathisia: A review: *Psychopharmacology* 1989; 97:1-11.

Book Chapters

1. Angrist B and Gershon S: Amphetamine induced schizophreniform psychosis. In: *Schizophrenia: Current Concepts and Research* (Siva Sankar, DV, Ph.D, ed.) Hicksville, N.Y: PJD Publications, 1969: 508-524.
2. Angrist B and Gershon S: Psychiatric sequelae of amphetamine use. In: *Psychiatric Complications of Medical Drugs*, (Shader R, Ed.) New York: Raven Press, 1972:175-199.

3. Angrist B and Gershon S: Recent studies on amphetamine psychosis: Theoretical implications. In: Drug Addiction, Vol IV, (Lal H and Singh J, eds.) New York, Stratton, Intercontinental Medical Book, 1974: 39-44.
4. Angrist B and Sudilovsky A: Central Nervous System stimulants: Historical and Clinical Aspects. In: Handbook of psychopharmacology (Iverson L, Iverson S and Synder, S, eds.) N.Y: Plenum Press, 1978: Vol 11:99-165.
5. Cancro R and Angrist B: Are drugs more than palliative in the treatment of schizophrenia. In: Controversies in Psychiatry (J.P. Brady and H.K. Brodie, eds.) W.B. Saunders, 1978:199-214.
6. Serby M, Angrist B and Lieberman A: Psychiatric effects of bromocryptine on lergotriple in Parkinsonian patients. In: Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects, edited by Goldstein M et al, New York: Raven Press, 1980.
7. Angrist B: The neurobiologically active benzamides and related compounds - Some historical aspects. In: The Benzamides, Edited by Stanley M and Rotrosen J. Advances in Biochemical; Psychopharmacology Raven Press, 1982: 55:1-6.
8. Angrist B: Psychoses induced by CNS stimulants and related drugs. In: Stimulants: Neurochemical and behavioral and Clinical perspectives. Creese, I, ed. New York: Raven Press, 1983.
9. Peselow E, Angrist B, Rubenstein M and Rotrosen J: Predictors of course after depot neuroleptic discontinuation: are there clinical guidelines? APA Clinical Insights Monograph Series. Lieberman J A and Kane J M, eds. Washington, D.C: American Psychiatric Press, Inc. 1986:16-32.
10. Angrist B: Clinical Studies of Central Nervous System Stimulants: A Selective Update. Engel, J, Orelan L, Ingvar, D. et al. (Eds.), Brain reward Systems and Abuse, NY: Raven Press, 1987: 109-127.
11. Angrist B: Pharmacologic Models of Schizophrenia. In: Henn, F A and DeLisi, L E (Eds.), Handbook of Schizophrenia. Vol 2, Neurochemistry and Neuropharmacology, Elsevier Science Publishers B.V. 1987: 391-424
12. Angrist B: Cocaine in the context of prior central nervous system stimulant epidemics. (In Volkow ND and Swan AC, Eds.) Cocaine in the Brain. New Brunswick and London: Rutgers U. Press, 1990:7-24
13. Angrist B and Schulz S C: Editors Introduction to The Neuroleptic Non-responsive Patient: Characterization and Treatment. pp XVII - XXVIII, APA Press Washington DC and London, 1990.
14. Adler LA, Angrist B, and Rotrosen J: Acute neuroleptic-induced akathisia. In (Lang AE and Weiner WJ, Eds.) Drug-induced movement disorders. Mt. Kisco, NY: Futura Publishing Co., Inc., 1992: 85-119
15. Angrist B: Ethical Issues Regarding Prospective Studies of Amphetamine Psychosis. The Journal of the California Alliance for the Mentally Ill, 1994:5(1):32-35.
16. Adler L and Angrist B: Neuroleptic-induced acute akathisia. In DSM-IV Source book, Francis AJ, Pincus HA, First MB et al eds. Washington DC: American Psychiatric Press. pp 744-746.
17. Angrist B: Amphetamine psychosis: Clinical variations of the syndrome In: (Cho KS and Segal DS, eds.) Amphetamine and its Analogs: Neuropsychopharmacology, Toxicology and Abuse, San Diego, New York, Boston, London, Sydney, Tokyo, Toronto: Academic Press (Division of Harcourt Brace & Co.) pp 387-414.

18. Angrist B., Sam Gershon's research unit in Bellevue Hospital, New York: A psychopharmacological "hot spot" in the 1970's. In: Ban T, Healy D, Shorter E (eds) The Triumph of Psychopharmacology and the Story of the CINP. Budapest: Animula, 2000: 250-254.

19. Adler L A, Rotrosen, J, Angrist B. Acute drug-induced akathisia. In: Factor S A, Lang, A E and Weiner, W J (eds) Drug Induced Movement Disorders. pages 140-173. Blackwell/Futura. 2005.

Abstracts

1. Adler L, Angrist B, Duncan E, Kim A, Fritz P, Rotrosen J: Beta blockers in akathisia updated: toward understanding the effect (abstract). *Schizophrenia Research* 1989;2:241.
2. Duncan E, Angrist B, Adler L, Corwin J and Rotrosen J: Pharmacologic challenge in akathisia variants (abstract). *Schizophrenia Research* 2:242, 189.
3. Clowner L, Halopigian K, Seiple W, Angrist B, Kupersmith M: (Abstract) Dopamine blockade has no effect on the human flash ERG ARVO 1991.
4. Wong DF, Hong C, Yokoi F, Schlaepfer T, Imperial A, Pearlson GD, Marenco S, Civelek C, Nestadt G, Ravert H, Dannals RF, Angrist B: Gjedde, Johns Hopkins Med. Inst. Baltimore, MD: NYU, NY; Aarhus U, DK: Imaging human intrasynaptic dopamine release by IV cocaine and amphetamine (Abstract) Soc. for Nuc. Med. Annual Meeting.

Letters to Editors

1. Sofair J, Campion J and Angrist B: High Dose trihexphenidyl abuse with psychological dependence. *J Clin Psychopharmacol* 1983; 3:263-264.
2. Adler L, Angrist B, Lautin A and Rotrosen J: Differential effects of TCA's on MAP in a hypertensive patient. *J Clin Psychopharmacol* 1983; 3:122.
3. Brody D, Schweitzer J, Angrist B, Rotrosen J and Friedhoff A: Lack of effect of carbidopa on plasma homovanillic acid levels in normal volunteers. *Psychiatry Res*, 1987; 21:185-187.
4. Adler L, Reiter S, Corwin J, Hemdal P, Angrist B and Rotrosen J: Benztropine and propranolol in akathisia. *Biol Psychiatry*, 1988; 23:211-213.
5. Bartlik B, Gallanter M and Angrist B: Dimenhydrinate addiction in a schizophrenic woman. *Clin Psychiatry*, 1989; 50: 47.
6. Adler L, Duncan E, Reiter S, Rotrosen J and Angrist B: Absence of effect of calcium channel antagonists on extrapyramidal symptoms. *Brit J Psychiat*, 1989; 153:26.
7. Fernandez-Bouzas A, Angrist B, Hemdal P, Alder L and Rotrosen J: Basal ganglia Calcification in schizophrenia. *Biol Psychiatry* 1990; 27:682-685.
8. Adler L, Angrist B and Rotrosen J: Metoprolol versus propranolol. *Biol Psychiatry* 1990; 27:673-675.